Absci Corporation (ABSI) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript

SA Transcripts159.09K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Absci Corporation (ABSI) 2026 KeyBanc Capital Markets Healthcare Virtual Forum March 17, 2026 1:30 PM EDT Company Participants Zachariah Jonasson - Chief Business Officer & CFOAlexander Khan - CVP of Finance & Head of Investor Relations Conference Call Participants Scott Schoenhaus - KeyBanc Capital Markets Inc., Research Division Presentation Scott SchoenhausKeyBanc Capital Markets Inc., Research Division Welcome, everyone, to our Virtual Health Care Forum. My name is Scott Schoenhaus. I'm the health care tech analyst here at KeyBanc. Happy to have Absci join us for our fireside chat. We have Zach Jonasson, CFO; and Alex Kahn, VP of Investor Relations. Thank you both for joining. Question-and-Answer Session Scott SchoenhausKeyBanc Capital Markets Inc., Research Division I guess Zach and Alex, I'll pass the floor to you. Maybe give a brief high-level high-level background on Absci for anyone that's new to our fireside chat. Zachariah JonassonChief Business Officer & CFO Sure. And first off, thanks for having us, Scott. We really appreciate it. I appreciate the opportunity to have the discussion. Zach Jonasson, I'm the CFO. I guess a quick high level on Absci. We're using generative AI to design antibody-based therapeutics. And we've been focused on this problem for the past 4 to 5 years, leveraging a lot of our own sort of lab-in-the-loop process to advance our model development. And I think what's really exciting about where we are today is, we're not just designing molecules in silico. We're not just making kits. We're actually making molecules that we're advancing into the clinic. And so we have a lead program, our flagship program today. ABS-201 is an AI designed antibody targeting the prolactin receptor. We think it's got very good developability, very strong characteristics, good half-life and we are advancing that currently in a Phase I/IIa study in androgenetic